#  @DaiichiSankyoUS Daiichi Sankyo US Daiichi Sankyo US posts on X about $8750t, $6417t, $4568t, breast cancer the most. They currently have [-----] followers and [---] posts still getting attention that total [---] engagements in the last [--] hours. ### Engagements: [---] [#](/creator/twitter::1169299794696818688/interactions)  - [--] Week [---] -68% - [--] Month [-----] -32% - [--] Months [------] -91% - [--] Year [-------] -96% ### Mentions: [--] [#](/creator/twitter::1169299794696818688/posts_active)  - [--] Month [--] -91% - [--] Months [--] +2.90% - [--] Year [--] +245% ### Followers: [-----] [#](/creator/twitter::1169299794696818688/followers)  - [--] Week [-----] -0.09% - [--] Month [-----] -0.09% - [--] Months [-----] +0.39% - [--] Year [-----] +1.70% ### CreatorRank: undefined [#](/creator/twitter::1169299794696818688/influencer_rank)  ### Social Influence **Social category influence** [stocks](/list/stocks) [technology brands](/list/technology-brands) [finance](/list/finance) [countries](/list/countries) [social networks](/list/social-networks) **Social topic influence** [$8750t](/topic/$8750t) #30, [$6417t](/topic/$6417t) #30, [$4568t](/topic/$4568t) #6, [breast cancer](/topic/breast-cancer), [click the](/topic/click-the), [award](/topic/award), [the first](/topic/the-first), [link](/topic/link), [youtube](/topic/youtube), [science](/topic/science) **Top accounts mentioned or mentioned by** [@astrazenecaus](/creator/undefined) [@myesmo](/creator/undefined) [@merck](/creator/undefined) [@sabcssanantonio](/creator/undefined) [@iaslc](/creator/undefined) [@worldadc](/creator/undefined) [@hbanet](/creator/undefined) [@galienfdn](/creator/undefined) [@derreckkayongo](/creator/undefined) [@citeline](/creator/undefined) [@usfda](/creator/undefined) [@ufpharmacy](/creator/undefined) [@hncalliance](/creator/undefined) [@afidrocolombia](/creator/undefined) [@asco](/creator/undefined) [@atoppsummit](/creator/undefined) [@gracequest](/creator/undefined) [@biopharmadive](/creator/undefined) [@pharmavoice](/creator/undefined) [@fda](/creator/undefined) **Top assets mentioned** [Merck & Co., Inc. (MRK)](/topic/merck) ### Top Social Posts Top posts by engagements in the last [--] hours "Our heritage is mostly Japanese but there is a dose of New York/New Jersey in our origin story. In [----] Dr. Jokichi Takamine the 1st president of Sankyo Co. Ltd. moved his laboratory from NYC to Clifton NJ where penicillinase was produced during WWII #FlashbackFriday" [X Link](https://x.com/DaiichiSankyoUS/status/1651980180259323905) 2023-04-28T16:02Z [----] followers, [---] engagements "Happy #IndependenceDay Whether you celebrate with flags fireworks friends or food take a moment to honor the courage of those who fought for the freedoms we enjoy today. Thank you to all who serve or have served including our @DaiichiSankyoUS veterans https://bit.ly/3NeyKLI https://bit.ly/3NeyKLI" [X Link](https://x.com/DaiichiSankyoUS/status/1676290087540105216) 2023-07-04T18:01Z [----] followers, [---] engagements "Our largest fellowship class to date this year we welcomed fellows from as far as Guyana & England to right here in NJ. Watch for more about [--] of our #fellows & their goals post-fellowship - Click for more stories:" [X Link](https://x.com/DaiichiSankyoUS/status/1704858796932116988) 2023-09-21T14:03Z [----] followers, [---] engagements "Register now @GalienFdn Week of Innovation series to feature our own Eric Richards Senior Vice President Head of Global Regulatory Affairs Oct. [--]. Register here:" [X Link](https://x.com/DaiichiSankyoUS/status/1716788085109698959) 2023-10-24T12:05Z [----] followers, [---] engagements "A powerful reminder of Dr. Martin Luther King Jr.'s enduring legacy of activism service and pursuit of equality we challenge ourselves daily to ask "what are you doing for others" We take action this #MLKDay for each other our communities and the patients we serve" [X Link](https://x.com/DaiichiSankyoUS/status/1746902557279269195) 2024-01-15T14:30Z [----] followers, [---] engagements "Founder of the Global Soap Project renowned entrepreneur and advocate for social change @DerreckKayongo inspired us this #Juneteenth to continue persevering for unity diversity and inclusion for alleach other the healthcare industry and the patients we serve" [X Link](https://x.com/DaiichiSankyoUS/status/1803838393219981670) 2024-06-20T17:12Z [----] followers, [---] engagements "Whats the scoop on Dale Shuster Senior Vice President Global Head of Precision Medicine at Daiichi Sankyo On #NationalIceCreamDay read about how Dale blends his passions for science ice cream and the ability to care for patients. #DSProud #PrecisionMedicine" [X Link](https://x.com/DaiichiSankyoUS/status/1815001277052465499) 2024-07-21T12:30Z [----] followers, [---] engagements "We aim to improve patient lives using groundbreaking technology. Explore our 70+ ongoing clinical trials" [X Link](https://x.com/DaiichiSankyoUS/status/1832388353028976777) 2024-09-07T12:00Z [----] followers, 2M engagements "Join us at #ESMO24 Visit booth #303 for an in depth look at Daiichi Sankyos latest R&D developments and learn how our craft is shaping the future of healthcare. And catch up on the latest episodes of Where Craft Meets only on YouTube" [X Link](https://x.com/DaiichiSankyoUS/status/1833837901324710195) 2024-09-11T12:00Z [----] followers, 281.1K engagements "Translating science for patients + patient insights for scientists. Gissoo DeCotiis Global Head of Advocacy & Strategic Relations has dedicated her career to ensuring patients are informed heard + supported. Read her story: 👉 #DSProud https://bit.ly/4h9oAdK https://bit.ly/4h9oAdK" [X Link](https://x.com/DaiichiSankyoUS/status/1846568579614859742) 2024-10-16T15:07Z [----] followers, 167.7K engagements "#News: During #ESMOAsia24 @DaiichiSankyoUS presented a pooled analysis of the TROPION-Lung05 phase [--] & TROPION-Lung01 phase [--] trials for patients w/ advanced or metastatic EGFR-mutated #NSCLC in collaboration w/ @AstraZenecaUS. Click the image to learn more" [X Link](https://x.com/DaiichiSankyoUS/status/1865041681298657495) 2024-12-06T14:32Z [----] followers, [---] engagements "#News: @DaiichiSankyoUS and @Merck have been recognized with the [----] Deal of the Year award by the @Citeline Scrip Awards. A testament to the combined commitment of both companies to help people impacted by cancer around the world" [X Link](https://x.com/DaiichiSankyoUS/status/1866860728034136518) 2024-12-11T15:00Z [----] followers, [---] engagements "Honoring Dr. Toshinori Agatsuma Executive Officer Head of Research Daiichi Sankyo Co. Ltd. A true scientific innovator who leaves an immeasurable legacy on the global oncology community as a pioneer of hope for countless people impacted by cancer" [X Link](https://x.com/DaiichiSankyoUS/status/1869766475587932429) 2024-12-19T15:27Z [----] followers, 406.6K engagements "🎇Happy Holidays and THANK YOU to all who work tirelessly to help make an impact for those facing life's toughest challenges. Watch our #YearInReview for how our passion for innovation and compassion for patients came to life in [----]. #DSProud" [X Link](https://x.com/DaiichiSankyoUS/status/1871243119489937598) 2024-12-23T17:15Z [----] followers, [---] engagements "Explore the journey of Stu Mackey Global Head of Business Development at Daiichi Sankyo as he shares his unique craft of building connections & how it helps bring innovation for the patients of today and tomorrow: https://bit.ly/3PqkxNu https://bit.ly/3PqkxNu" [X Link](https://x.com/DaiichiSankyoUS/status/1878838022516388240) 2025-01-13T16:14Z [----] followers, 154.8K engagements "Stu Mackey Global Head of Business Development @DaiichiSankyoUS shares his insights on the art of crafting strategic partnerships that benefit patients partners and investors alike. Watch "Where Craft Meets - Partnerships" to learn more" [X Link](https://x.com/DaiichiSankyoUS/status/1878843145015931191) 2025-01-13T16:34Z [----] followers, 354.7K engagements "The art of a "good deal" unfolds in the latest episode of "Where Craft Meets - Partnerships" featuring Stu Mackey @DaiichiSankyoUS Global Head of Business Development. Watch now only on YouTube" [X Link](https://x.com/DaiichiSankyoUS/status/1878843145020207522) 2025-01-13T16:34Z [----] followers, 310.3K engagements "At @DaiichiSankyoUS our mission is to deliver innovative medicines to patients in need. Watch Where Craft Meets Partnerships to hear from our Stu Mackey Global Head of Business Development on how he applies his craft of Building Connections with this mission:" [X Link](https://x.com/DaiichiSankyoUS/status/1878843145292571030) 2025-01-13T16:34Z [----] followers, 326K engagements "#BreakingNews: Our HER2 directed #ADC has received @US_FDA approval for certain patients with metastatic breast cancer in collaboration w/ @AstraZenecaUS. Click the link to learn more about this latest FDA approval: http://bit.ly/40NYA1f http://bit.ly/40NYA1f" [X Link](https://x.com/DaiichiSankyoUS/status/1884034810177544225) 2025-01-28T00:24Z [----] followers, [---] engagements "The potential to improve cancer care and provide new hope to patients is a driving force behind everyone at Daiichi Sankyo. The trust and collaboration from patients allow us to push the limits of what exists today. Together we are creating new standards of care" [X Link](https://x.com/DaiichiSankyoUS/status/1890050868344701175) 2025-02-13T14:50Z [----] followers, [---] engagements "#NEWS: Today we announced positive topline overall survival results from the DESTINY-Gastric04 phase [--] trial in patients with previously treated HER2 positive metastatic #GastricCancer in collaboration with @AstraZenecaUS. Click the image to learn more" [X Link](https://x.com/DaiichiSankyoUS/status/1896549859131605411) 2025-03-03T13:14Z [----] followers, [----] engagements "@UFPharmacy Thank you we are proud to be a partner in your initiative" [X Link](https://x.com/DaiichiSankyoUS/status/1897391601049014551) 2025-03-05T20:59Z [----] followers, [--] engagements "When it comes to medicine development success is achieved by our people passionate experts working to combine their unique crafts with one purpose in mind challenging the status quo to help the patients of tomorrow. Swipe to see what our employees have to say about the team" [X Link](https://x.com/DaiichiSankyoUS/status/1900238023813415226) 2025-03-13T17:30Z [----] followers, [---] engagements "In a world overflowing with data and noise the most powerful tool we have is the timeless art of storytelling. Watch Kim Wix Executive Director of Corporate Communications @DaiichiSankyoUS as she shares her unique craft of storytelling to evoke emotion & why choosing the right words has the power to connect and inspire us. Watch here: #Leadership #Innovation #Communication #DSProud https://bit.ly/4kqs9Od https://bit.ly/4kqs9Od" [X Link](https://x.com/DaiichiSankyoUS/status/1900548151691407689) 2025-03-14T14:02Z [----] followers, [--] engagements "@hncalliance @hncalliance Thank you we are proud to be a partner in your initiative" [X Link](https://x.com/DaiichiSankyoUS/status/1901698492935917794) 2025-03-17T18:13Z [----] followers, [--] engagements "#NEWS: @DaiichiSankyoUS has initiated the DESTINY-Gastric05 phase [--] trial in previously untreated patients with unresectable locally advanced or metastatic HER2 positive gastric or gastroesophageal junction (GEJ) cancer in collaboration with @AstraZenecaUS. Click for more" [X Link](https://x.com/DaiichiSankyoUS/status/1906688484980433338) 2025-03-31T12:42Z [----] followers, [---] engagements "#NEWS: Today we announced topline results from the DESTINY-Breast09 phase [--] trial in certain patients with previously untreated HER2 positive metastatic breast cancer in collaboration with @AstraZenecaUS. Click the image to learn more. #mBC #HER2" [X Link](https://x.com/DaiichiSankyoUS/status/1914313518398025896) 2025-04-21T13:41Z [----] followers, [---] engagements "@afidro_colombia Thank you we appreciate your message" [X Link](https://x.com/DaiichiSankyoUS/status/1919950939345064276) 2025-05-07T03:02Z [----] followers, [--] engagements "#NEWS: Today we announced topline results from the DESTINY-Breast11 phase [--] trial in patients with high-risk #HER2 positive early-stage breast cancer in collaboration with @AstraZenecaUS. Click the image to learn more. #BreastCancer #NationalCancerResearchMonth #OncologyNews" [X Link](https://x.com/DaiichiSankyoUS/status/1920197395494653974) 2025-05-07T19:21Z [----] followers, [---] engagements "#BREAKINGNEWS: @DaiichiSankyoUS has initiated the IDeate-Esophageal01 phase [--] trial in certain patients with pretreated advanced or metastatic esophageal squamous cell carcinoma (#ESCC) in collaboration with @Merck. Click the link for more information" [X Link](https://x.com/DaiichiSankyoUS/status/1924464525207605545) 2025-05-19T13:57Z [----] followers, [---] engagements "#ASCO25NEWS: Throughout @ASCO we will present more than [--] abstracts across our oncology portfolio including two late-breaking oral presentations. Click to learn more about the specific presentations and follow us during #ASCO25 for more data updates: https://bit.ly/3ZtVSg8 https://bit.ly/3ZtVSg8" [X Link](https://x.com/DaiichiSankyoUS/status/1925674680729407566) 2025-05-22T22:06Z [----] followers, [---] engagements "Metastatic Breast Cancer is different. It is more complex than early-stage #BreastCancer requiring alternative treatment plans. Learn about the nuances & how @DaiichiSankyoUS is developing innovations that may change the treatment landscape for patients. Click now to read. #mBC" [X Link](https://x.com/DaiichiSankyoUS/status/1928084203305857067) 2025-05-29T13:41Z [----] followers, [---] engagements "#BREAKINGNEWS: Today at a late breaking oral presentation at #ASCO25 positive results from the DESTINY-Gastric04 phase [--] trial were presented in collaboration with @AstraZenecaUS. Click the image to learn more. #GastricCancer #HER2Positive" [X Link](https://x.com/DaiichiSankyoUS/status/1928787262910661103) 2025-05-31T12:14Z [----] followers, [---] engagements "#NEWS: Results from the TROPION-Lung02 & TROPION-Lung04 phase 1b trials & NeoCOAST-2 phase [--] trial showing promising tumor responses in patients with early and advanced #NSCLC were presented today at #ASCO25 in collaboration with @AstraZenecaUS. Click the image to learn more" [X Link](https://x.com/DaiichiSankyoUS/status/1929165081192907236) 2025-06-01T13:16Z [----] followers, [---] engagements "#BREAKINGNEWS: Today during a special late breaking oral presentation at #ASCO25 results from the DESTINY-Breast09 phase [--] trial were presented in collaboration with @AstraZenecaUS. Click the image to learn more. #mBC #HER2Positive" [X Link](https://x.com/DaiichiSankyoUS/status/1929510596103344206) 2025-06-02T12:09Z [----] followers, [---] engagements "@atoppsummit @atoppsummit Thank you we are proud to be a sponsor for this event" [X Link](https://x.com/DaiichiSankyoUS/status/1929632892449091640) 2025-06-02T20:15Z [----] followers, [--] engagements "@Grace_Quest Thank you we appreciate your message" [X Link](https://x.com/DaiichiSankyoUS/status/1929743372152959368) 2025-06-03T03:34Z [----] followers, [--] engagements "Register now for the @BioPharmaDive & @pharmavoice virtual event this Thursday featuring @DaiichiSankyoUS CEO Ken Keller as he discusses the ins and outs of Building a blockbuster ADC franchise. Register here: https://bit.ly/43EKRdd https://bit.ly/43EKRdd" [X Link](https://x.com/DaiichiSankyoUS/status/1929913022182515132) 2025-06-03T14:48Z [----] followers, [---] engagements "#BREAKINGNEWS: @DaiichiSankyoUS has initiated the DESTINY-Endometrial01 phase [--] trial in patients with previously untreated HER2 expressing advanced endometrial cancer in collaboration with @AstraZenecaUS. Click the image for more information. #EndometrialCancer" [X Link](https://x.com/DaiichiSankyoUS/status/1932060685061837055) 2025-06-09T13:02Z [----] followers, [---] engagements "#BREAKINGNEWS: @DaiichiSankyoUS has initiated the IDeate-Prostate01 phase [--] trial in certain patients with pretreated metastatic castration-resistant prostate cancer in collaboration with @Merck. Click the link for more information: https://bit.ly/3G7ERSx https://bit.ly/3G7ERSx" [X Link](https://x.com/DaiichiSankyoUS/status/1935294888439947745) 2025-06-18T11:13Z [----] followers, [---] engagements "#BreakingNews: Today the @FDA approved our TROP2 directed DXd #ADC for previously treated adult patients with locally advanced or metastatic #EGFR-mutated #NSCLC in collaboration w/ @AstraZenecaUS. Click the image to learn more" [X Link](https://x.com/DaiichiSankyoUS/status/1937262762520117312) 2025-06-23T21:33Z [----] followers, [---] engagements "There is more to metastatic breast cancer than the science. Patricia Judson M.D. Vice President U.S. Medical Affairs discusses the importance of recognizing the different tone and unique needs of patients with #mBC. Click now to read the full story. #MetastaticBreastCancer" [X Link](https://x.com/DaiichiSankyoUS/status/1938278363665469446) 2025-06-26T16:49Z [----] followers, [---] engagements "Behind every medicine is a story. At Daiichi Sankyo our experts combine precision and purpose to drive innovation. Discover how their unique crafts help transform science into medicines for the patients of today and tomorrow. 🔗 https://bit.ly/3TOL88S https://bit.ly/3TOL88S" [X Link](https://x.com/DaiichiSankyoUS/status/1942592005797789800) 2025-07-08T14:30Z [----] followers, [---] engagements "#BREAKINGNEWS: Today we announced the publication of final long-term efficacy and safety results from the open-label extension of the ENLIVEN phase [--] trial of our medicine in patients with tenosynovial giant cell tumor. Click the image to learn more. #TGCT" [X Link](https://x.com/DaiichiSankyoUS/status/1942919341491863725) 2025-07-09T12:10Z [----] followers, [---] engagements "#NEWS: The FDA granted Breakthrough Therapy Designation for our HER2 directed #ADC as part of a combination regimen for the first-line treatment of adult patients w/ HER2 positive #mBC in collaboration w/ @AstraZenecaUS. This is the 13th BTD across our oncology portfolio" [X Link](https://x.com/DaiichiSankyoUS/status/1945817488941547788) 2025-07-17T12:06Z [----] followers, [---] engagements "Ray Bedeaux simplifies complex oncology processes helping Daiichi Sankyo focus on what matters mostpatients. Join us and help shape the future of healthcare together" [X Link](https://x.com/DaiichiSankyoUS/status/1947302792990970169) 2025-07-21T14:28Z [----] followers, 203.6K engagements "Delivering medicines is complex but Ray Bedeauxs craft of synthesis ensures Daiichi Sankyo focuses on what matters most for patients. Discover how Daiichi Sankyo is shaping the future of medicine" [X Link](https://x.com/DaiichiSankyoUS/status/1947302793011777637) 2025-07-21T14:28Z [----] followers, 226.9K engagements "Ray Bedeaux turns complexity into impact. His craft "Synthesis" ensures the critical medicines we create reach patients who need them most. Share your unique craft below and how it is shaping the future. Read our Company Brochure to learn how we are making an impact: https://bit.ly/3IEHQmr https://bit.ly/3IEHQmr" [X Link](https://x.com/DaiichiSankyoUS/status/1947310397561647530) 2025-07-21T14:59Z [----] followers, [---] engagements "This is the story of a promise kept. After witnessing his father experience a devastating battle with cancer Ray Bedeaux made a promiseto dedicate himself to the field of oncology. Dont miss this inspiring story: #WhereCraftMeets #Oncology #PatientCare #Innovation https://bit.ly/4ooqAST https://bit.ly/4ooqAST https://bit.ly/4ooqAST https://bit.ly/4ooqAST" [X Link](https://x.com/DaiichiSankyoUS/status/1953128721864638908) 2025-08-06T16:19Z [----] followers, [---] engagements "#BREAKINGNEWS: At the [----] @IASLC Annual Meeting we will share data during a late-breaking oral presentation from the IDeate-Lung01 phase [--] trial for patients with pretreated extensive-stage small cell lung cancer. Click to learn more & follow us during #WCLC25 for more" [X Link](https://x.com/DaiichiSankyoUS/status/1955966519894020159) 2025-08-14T12:15Z [----] followers, [---] engagements "#BREAKINGNEWS: The FDA granted Breakthrough Therapy Designation for one of our investigational medicines for adult patients with extensive-stage small cell lung cancer in collaboration with @Merck. This is the 14th BTD across our oncology portfolio. #SCLC #CancerResearch" [X Link](https://x.com/DaiichiSankyoUS/status/1957402203217404019) 2025-08-18T11:20Z [----] followers, [---] engagements "The not-so-hidden secret to our hiring success Empathy transparency and culture. Read how Daiichi Sankyo builds teams that thrive" [X Link](https://x.com/DaiichiSankyoUS/status/1961156562669404523) 2025-08-28T19:58Z [----] followers, [---] engagements "#BREAKINGNEWS: @DaiichiSankyoUS has initiated the HERTHENA-Breast04 phase [--] trial in patients with unresectable locally advanced or metastatic hormone receptor (HR) positive HER2 negative breast cancer in collaboration with @Merck. Click the link for more information. #mBC" [X Link](https://x.com/DaiichiSankyoUS/status/1961400473174643037) 2025-08-29T12:08Z [----] followers, [---] engagements "#BREAKINGNEWS: Late-breaking data from the IDeate-Lung01 phase [--] trial in patients with pretreated extensive-stage small cell lung cancer were presented during a late-breaking oral presentation at the [----] @IASLC Annual Meeting in collaboration with @Merck. Learn more. #WCLC25" [X Link](https://x.com/DaiichiSankyoUS/status/1964711023002222792) 2025-09-07T15:23Z [----] followers, [---] engagements "#BREAKINGNEWS: The FDA granted Breakthrough Therapy Designation for our investigational medicine for certain adult patients with platinum-resistant ovarian cancer being developed in collaboration w/ @Merck. Click the image to learn more. #OvarianCancer #CancerResearch" [X Link](https://x.com/DaiichiSankyoUS/status/1967547631800033759) 2025-09-15T11:14Z [----] followers, [---] engagements "#BREAKINGNEWS: The FDA accepted & granted Priority Review of the sBLA for our HER2 directed DXd ADC as part of a combination regimen for the first-line treatment of adult patients w/ metastatic HER2 positive breast cancer in collaboration w/ @AstraZenecaUS. #BreastCancer" [X Link](https://x.com/DaiichiSankyoUS/status/1970804907604316659) 2025-09-24T10:58Z [----] followers, [---] engagements "#NEWS: Today we announced positive topline results from the DESTINY-Breast05 phase [--] trial for patients with high-risk HER2 positive early breast cancer in collaboration w/ @AstraZenecaUS; our second positive phase [--] trial in HER2 positive early breast cancer. Click for more" [X Link](https://x.com/DaiichiSankyoUS/status/1972635233892868513) 2025-09-29T12:11Z [----] followers, [---] engagements "After a 2-year PharmD fellowship Andrew found his calling as a medical reviewer. Learn how he honors his mother and empowers patients every day by translating complex science into trust" [X Link](https://x.com/DaiichiSankyoUS/status/1973033628751020217) 2025-09-30T14:34Z [----] followers, [---] engagements "Our team at Daiichi Sankyo is committed to raising awareness this month for #breastcancer research. Watch a message from our CEO Ken Keller to learn what #BCAM means to us" [X Link](https://x.com/DaiichiSankyoUS/status/1316723831952814083) 2020-10-15T12:53Z [----] followers, [--] engagements "It was incredible how these doctors & nurses were able to repair this broken heart no bigger than a walnut. Michael Grosso VP Global Head of Specialty Medicine Development at Daiichi Sankyo discusses life as a former heart surgeon & his fulfilling career. #Heartmonth" [X Link](https://x.com/DaiichiSankyoUS/status/1760017263963275353) 2024-02-20T19:03Z [----] followers, [---] engagements "#BreakingNews: Throughout @SABCSSanAntonio @myESMO and @ASH_hematology @Daiichi Sankyo US will highlight progress across our oncology portfolio in multiple solid and blood cancers. Click the image for full details on our #SABCS24 #ESMOASIA24 & #ASH24 data" [X Link](https://x.com/DaiichiSankyoUS/status/1863570147992313922) 2024-12-02T13:05Z [----] followers, [---] engagements "Daiichi Sankyo today announced Hiroyuki Okuzawa as the new global CEO effective April [--] [----]. Mr. Okuzawa currently Representative Director President and COO will succeed Sunao Manabe who will continue as the Representative Director and Executive Chairperson" [X Link](https://x.com/DaiichiSankyoUS/status/1885311845084643525) 2025-01-31T12:59Z [----] followers, [---] engagements "On #WorldCancerDay we stand united with the global oncology community to recognize and honor the unique stories of those impacted by cancer. No two cancer treatment journeys are alike but we all share the same goal. #UnitedByUnique" [X Link](https://x.com/DaiichiSankyoUS/status/1886750984581603659) 2025-02-04T12:17Z [----] followers, [---] engagements "Patients don't think like scientists - and they shouldn't have to. @GDbinkys team helps translate highly complex topics like #CancerResearch into easy-to-understand resources for patients and caregivers. #PatientCare #Advocacy https://bit.ly/4aiXFsL https://bit.ly/4aiXFsL" [X Link](https://x.com/DaiichiSankyoUS/status/1889366289291907230) 2025-02-11T17:30Z [----] followers, [---] engagements "Simon King a seasoned HR leader with a scientific foundation honed his craft of "listening" to uncover insights and perspectives from others that make a difference. Join us for a conversation with our @DaiichiSankyoUS Chief People Officer to learn about his career journey and his unique perspective on teamwork. Watch the full episode now on YouTube: https://bit.ly/3Qqyqvl https://bit.ly/3Qqyqvl" [X Link](https://x.com/DaiichiSankyoUS/status/1894046884882481288) 2025-02-24T15:29Z [----] followers, [--] engagements "#BREAKINGNEWS: The FDA accepted the sBLA for our HER2 directed DXd #ADC followed by a combination regimen for the treatment of adult patients w/ high-risk #HER2 positive early-stage breast cancer prior to surgery in collaboration w/ @AstraZenecaUS. Click to learn more" [X Link](https://x.com/DaiichiSankyoUS/status/1973346517252767839) 2025-10-01T11:17Z [----] followers, [---] engagements "#BREAKINGNEWS: Today we announced the establishment of the Daiichi Sankyo Research Institute in San Diego marking our third research institute outside of our flagship research center in Japan. Click the image to learn more. #ResearchInstitute #PharmaResearch" [X Link](https://x.com/DaiichiSankyoUS/status/1973737189914866085) 2025-10-02T13:09Z [----] followers, [---] engagements "#BREAKINGNEWS: Today we announced positive topline results from the TROPION-Breast02 phase [--] trial for patients with locally recurrent inoperable or metastatic triple negative breast cancer (#TNBC) in collaboration with @AstraZenecaUS. Click the image to learn more. #TNBC" [X Link](https://x.com/DaiichiSankyoUS/status/1975158662407840209) 2025-10-06T11:18Z [----] followers, [---] engagements "#BREAKINGNEWS: Daiichi Sankyo joins @BioLabs the leading international innovation platform and network of premier shared laboratory spaces as Platinum Sponsor; providing BioLabs with direct access to Daiichi Sankyo scientific leaders and expertise. Click the image for more" [X Link](https://x.com/DaiichiSankyoUS/status/1975520302286450785) 2025-10-07T11:15Z [----] followers, [---] engagements "#NEWS: Throughout @MyESMO we will present more than [--] abstracts including two back-to-back presentations during Presidential Symposium I featuring data from the DESTINY-Breast11 & DESTINY-Breast05 phase [--] trials & late-breaking data from the TROPION-Breast02 phase [--] trial" [X Link](https://x.com/DaiichiSankyoUS/status/1977697830606361036) 2025-10-13T11:28Z [----] followers, [---] engagements "#BREAKINGNEWS: Today during a mini oral session at @MyESMO Daiichi Sankyo announced initial results from one substudy of the TROPION-PanTumor03 phase [--] trial in patients with locally advanced or metastatic urothelial cancer. Click to learn more. #BladderCancer #ESMO25" [X Link](https://x.com/DaiichiSankyoUS/status/1979189488745419041) 2025-10-17T14:15Z [----] followers, [---] engagements "#BREAKINGNEWS: Today during Presidential Symposium I at @MyESMO Daiichi Sankyo announced the first neoadjuvant data from the DESTINY-Breast11 phase [--] trial for patients with high-risk HER2 positive early-stage breast cancer. Click to learn more. #HER2" [X Link](https://x.com/anyuser/status/1979558640379105786) 2025-10-18T14:42Z [----] followers, [---] engagements "#BREAKINGNEWS: Today during Presidential Symposium I at @MyESMO Daiichi Sankyo announced new post-neoadjuvant data from the DESTINY-Breast05 phase [--] trial in patients with HER2 positive high-risk early breast cancer. Click the image to learn more. #CancerResearch #HER2" [X Link](https://x.com/anyuser/status/1979561741869863357) 2025-10-18T14:54Z [----] followers, [---] engagements "#BREAKINGNEWS: Today at @MyESMO Daiichi Sankyo announced late-breaking data from the TROPION-Breast02 phase [--] trial in patients w/ metastatic triple negative breast cancer (#TNBC) in the first-line treatment setting. Click to learn more. #ESMO25" [X Link](https://x.com/anyuser/status/1979867443532288510) 2025-10-19T11:09Z [----] followers, [---] engagements "#BREAKINGNEWS: Today at @MyESMO Daiichi Sankyo announced results from the phase [--] part of the REJOICE-Ovarian01 phase 2/3 trial in certain patients with platinum-resistant ovarian cancer. Click the image to learn more. #OvarianCancer #CancerResearch #ESMO25" [X Link](https://x.com/anyuser/status/1979897206326059271) 2025-10-19T13:07Z [----] followers, [---] engagements "#BREAKINGNEWS: During @MyESMO Daiichi Sankyo announced data from our TA-MUC1 directed DXd ADC first-in-human phase 1/2 trial. This is the sixth DXd ADC from our oncology pipeline. Click to learn more & follow us during #ESMO25 for the latest data updates from Daiichi Sankyo" [X Link](https://x.com/anyuser/status/1979901319180902826) 2025-10-19T13:23Z [----] followers, [---] engagements "For Alex Borchard building a positive workplace culture and bringing hope to patients with cancer has never been more personal. Read her inspiring story and join us in supporting patients everywhere. https://bit.ly/4oNiHpD https://bit.ly/4oNiHpD" [X Link](https://x.com/anyuser/status/1983263436688478632) 2025-10-28T20:03Z [----] followers, [---] engagements "#BREAKINGNEWS: @DaiichiSankyoUS has initiated the DESTINY-Lung06 phase [--] trial in patients with HER2 Overexpressing Metastatic Non-Squamous Non-Small Cell Lung Cancer. Click for more information: #NonSquamousNSCLC #HER2 https://bit.ly/47txrTm https://bit.ly/47txrTm" [X Link](https://x.com/anyuser/status/1984230620198015158) 2025-10-31T12:06Z [----] followers, [---] engagements "#BREAKINGNEWS: @DaiichiSankyoUS has initiated a phase [--] trial evaluating our first STING agonist ADC in patients with advanced metastatic or unresectable solid tumors. #Oncology #CancerResearch https://bit.ly/44129lI https://bit.ly/44129lI" [X Link](https://x.com/anyuser/status/1987855137000259796) 2025-11-10T12:09Z [----] followers, [----] engagements "#BREAKINGNEWS: Our proprietary DXd ADC Technology has been won the Best ADC Platform Technology. In addition our TROP2 directed DXd ADC won the Best ADC Clinical Impact Award and our HER2 directed DXd ADC won the Best ADC Clinical Publication Award by @World_ADC" [X Link](https://x.com/anyuser/status/1989016287184306611) 2025-11-13T17:03Z [----] followers, [---] engagements "#BREAKINGNEWS: During @SABCSSanAntonio we will present new breast cancer clinical research from more than [--] abstracts across our DXd ADC portfolio including updates from five landmark trials. Click for the link to learn more: #SABCS25 https://bit.ly/48KxdI9 https://bit.ly/48KxdI9" [X Link](https://x.com/anyuser/status/1998003857708687422) 2025-12-08T12:16Z [----] followers, [---] engagements "#BREAKINGNEWS: We initiated the DESTINY-Ovarian01 phase [--] trial evaluating our HER2 directed ADC as a combination first-line maintenance therapy in patients with HER2 expressing advanced high-grade epithelial ovarian cancer. https://bit.ly/44iOdE5 https://bit.ly/44iOdE5" [X Link](https://x.com/anyuser/status/1998370568211706251) 2025-12-09T12:34Z [----] followers, [---] engagements "#BREAKINGNEWS: The FDA has approved our HER2 directed DXd ADC as part of a combination regimen for the first-line treatment of adult patients with HER2 positive metastatic breast cancer in collaboration with @AstraZenecaUS. #BreastCancerResearch https://bit.ly/3XWtnXq https://bit.ly/3XWtnXq" [X Link](https://x.com/anyuser/status/2000657531388223518) 2025-12-15T20:01Z [----] followers, [---] engagements "#ICYM any of the @DaiichiSankyoUS R&D milestones throughout [----] our annual Science & Technology Day is now available on demand. Hear from key leaders as they share significant clinical achievements across our #oncology portfolio. Click here: https://bit.ly/4p0D7uK https://bit.ly/4p0D7uK" [X Link](https://x.com/anyuser/status/2001291293570236444) 2025-12-17T14:00Z [----] followers, [---] engagements "#BREAKINGNEWS: @DaiichiSankyoUS has initiated the DESTINY-Endometrial02 phase [--] trial evaluating our HER2 directed ADC as an adjuvant treatment in patients with HER2 expressing #endometrialcancer in collaboration with @AstraZenecaUS. Click for more info: https://bit.ly/3KVbMwf https://bit.ly/3KVbMwf" [X Link](https://x.com/anyuser/status/2003073102675337581) 2025-12-22T12:00Z [----] followers, [---] engagements "#BREAKINGNEWS: The FDA has granted Breakthrough Therapy Designation for our HER2-directed DXd ADC as a post-neoadjuvant treatment in patients with HER2 positive early breast cancer in collaboration w/ @AstraZenecaUS. Click the link to learn more: https://bit.ly/3KYdYTK https://bit.ly/3KYdYTK" [X Link](https://x.com/anyuser/status/2003097449716740487) 2025-12-22T13:37Z [----] followers, [---] engagements "From all of us at Daiichi Sankyowishing you a healthy peaceful and hopeful New Year. Heres to creating better tomorrows together" [X Link](https://x.com/anyuser/status/2006697663593693427) 2026-01-01T12:03Z [----] followers, [---] engagements "#BREAKINGNEWS: @DaiichiSankyoUS has initiated the TROPION-Lung17 phase [--] trial in certain patients with previously treated TROP2 NMR positive locally advanced or metastatic nonsquamous nonsmall cell lung cancer in collaboration with @AstraZenecaUS. Learn more: https://bit.ly/3YCkaUA https://bit.ly/3YCkaUA" [X Link](https://x.com/anyuser/status/2011047274370011188) 2026-01-13T12:06Z [----] followers, [---] engagements "#BREAKINGNEWS: The FDA has granted Priority Review for the sBLA for our TROP2 directed DXd ADC for the treatment of certain adult patients with unresectable or metastatic triple negative breast cancer in collaboration with @AstraZenecaUS. #BreastCancerResearch #TNBC https://bit.ly/3M9rxAe https://bit.ly/3M9rxAe" [X Link](https://x.com/anyuser/status/2018656304936415522) 2026-02-03T12:02Z [----] followers, [---] engagements "#BREAKINGNEWS: @DaiichiSankyoUS has initiated a phase 1/2 trial evaluating our CD37 directed DXd ADC in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Learn more: https://bit.ly/4qcdVSD https://bit.ly/4qcdVSD" [X Link](https://x.com/anyuser/status/2019019210027155536) 2026-02-04T12:04Z [----] followers, [---] engagements "From leadership development to transformative cancer medicines our enterprise approach earned the first Global Impact Award Honorable Mention from @HBAnet. Thank you to our global teams. #DSProud #AscendWithHBA Today we are thrilled to announce @DaiichiSankyoUS as the winner of the [----] HBA Global Impact Award Honorable Mention Distinction Read the full announcement here: https://t.co/Qh8IsYISCh https://t.co/pxs492VZHY Today we are thrilled to announce @DaiichiSankyoUS as the winner of the [----] HBA Global Impact Award Honorable Mention Distinction Read the full announcement here:" [X Link](https://x.com/anyuser/status/2021228799774413070) 2026-02-10T14:24Z [----] followers, [---] engagements "Every role at Daiichi Sankyo is part of a bigger story. See how Tamys craftorchestrationconnects innovation to impact turning science into meaningful progress for patients" [X Link](https://x.com/DaiichiSankyoUS/status/2021678454740222309) 2026-02-11T20:11Z [----] followers, 11.1K engagements "Behind every medicine is a story. Meet Ray Bedeaux whose craft of synthesis helps Daiichi Sankyo simplify complex processes to focus on what matters mostpatients. Follow for the stories behind our medicines" [X Link](https://x.com/DaiichiSankyoUS/status/2021678454740230144) 2026-02-11T20:11Z [----] followers, 12.7K engagements "Behind every medicine is a story. Meet Ray Bedeaux whose craft of synthesis helps Daiichi Sankyo simplify complex processes to focus on what matters mostpatients. Follow for the stories behind our medicines" [X Link](https://x.com/DaiichiSankyoUS/status/2021678455491113125) 2026-02-11T20:11Z [----] followers, 41.6K engagements "From leadership development to transformative cancer medicines our enterprise approach earned the first Global Impact Award Honorable Mention from @HBAnet. Thank you to our global teams. #DSProud #AscendWithHBA Today we are thrilled to announce @DaiichiSankyoUS as the winner of the [----] HBA Global Impact Award Honorable Mention Distinction Read the full announcement here: https://t.co/Qh8IsYISCh https://t.co/pxs492VZHY Today we are thrilled to announce @DaiichiSankyoUS as the winner of the [----] HBA Global Impact Award Honorable Mention Distinction Read the full announcement here:" [X Link](https://x.com/anyuser/status/2021228799774413070) 2026-02-10T14:24Z [----] followers, [---] engagements "Today we are thrilled to announce @DaiichiSankyoUS as the winner of the [----] HBA Global Impact Award Honorable Mention Distinction Read the full announcement here: https://hbanet.org/news/2026/02/5/daiichi-sankyo-honored-global-impact-award-honorable-mention-healthcare https://hbanet.org/news/2026/02/5/daiichi-sankyo-honored-global-impact-award-honorable-mention-healthcare" [X Link](https://x.com/anyuser/status/2021222769040474253) 2026-02-10T14:00Z [----] followers, [---] engagements "#BREAKINGNEWS: @DaiichiSankyoUS has initiated a phase 1/2 trial evaluating our CD37 directed DXd ADC in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Learn more: https://bit.ly/4qcdVSD https://bit.ly/4qcdVSD" [X Link](https://x.com/anyuser/status/2019019210027155536) 2026-02-04T12:04Z [----] followers, [---] engagements "#BREAKINGNEWS: The FDA has granted Priority Review for the sBLA for our TROP2 directed DXd ADC for the treatment of certain adult patients with unresectable or metastatic triple negative breast cancer in collaboration with @AstraZenecaUS. #BreastCancerResearch #TNBC https://bit.ly/3M9rxAe https://bit.ly/3M9rxAe" [X Link](https://x.com/anyuser/status/2018656304936415522) 2026-02-03T12:02Z [----] followers, [---] engagements "#BREAKINGNEWS: @DaiichiSankyoUS has initiated the TROPION-Lung17 phase [--] trial in certain patients with previously treated TROP2 NMR positive locally advanced or metastatic nonsquamous nonsmall cell lung cancer in collaboration with @AstraZenecaUS. Learn more: https://bit.ly/3YCkaUA https://bit.ly/3YCkaUA" [X Link](https://x.com/anyuser/status/2011047274370011188) 2026-01-13T12:06Z [----] followers, [---] engagements "From all of us at Daiichi Sankyowishing you a healthy peaceful and hopeful New Year. Heres to creating better tomorrows together" [X Link](https://x.com/anyuser/status/2006697663593693427) 2026-01-01T12:03Z [----] followers, [---] engagements "#BREAKINGNEWS: The FDA has granted Breakthrough Therapy Designation for our HER2-directed DXd ADC as a post-neoadjuvant treatment in patients with HER2 positive early breast cancer in collaboration w/ @AstraZenecaUS. Click the link to learn more: https://bit.ly/3KYdYTK https://bit.ly/3KYdYTK" [X Link](https://x.com/anyuser/status/2003097449716740487) 2025-12-22T13:37Z [----] followers, [---] engagements "#BREAKINGNEWS: @DaiichiSankyoUS has initiated the DESTINY-Endometrial02 phase [--] trial evaluating our HER2 directed ADC as an adjuvant treatment in patients with HER2 expressing #endometrialcancer in collaboration with @AstraZenecaUS. Click for more info: https://bit.ly/3KVbMwf https://bit.ly/3KVbMwf" [X Link](https://x.com/anyuser/status/2003073102675337581) 2025-12-22T12:00Z [----] followers, [---] engagements "#ICYM any of the @DaiichiSankyoUS R&D milestones throughout [----] our annual Science & Technology Day is now available on demand. Hear from key leaders as they share significant clinical achievements across our #oncology portfolio. Click here: https://bit.ly/4p0D7uK https://bit.ly/4p0D7uK" [X Link](https://x.com/anyuser/status/2001291293570236444) 2025-12-17T14:00Z [----] followers, [---] engagements "#BREAKINGNEWS: The FDA has approved our HER2 directed DXd ADC as part of a combination regimen for the first-line treatment of adult patients with HER2 positive metastatic breast cancer in collaboration with @AstraZenecaUS. #BreastCancerResearch https://bit.ly/3XWtnXq https://bit.ly/3XWtnXq" [X Link](https://x.com/anyuser/status/2000657531388223518) 2025-12-15T20:01Z [----] followers, [---] engagements "#BREAKINGNEWS: We initiated the DESTINY-Ovarian01 phase [--] trial evaluating our HER2 directed ADC as a combination first-line maintenance therapy in patients with HER2 expressing advanced high-grade epithelial ovarian cancer. https://bit.ly/44iOdE5 https://bit.ly/44iOdE5" [X Link](https://x.com/anyuser/status/1998370568211706251) 2025-12-09T12:34Z [----] followers, [---] engagements "#BREAKINGNEWS: During @SABCSSanAntonio we will present new breast cancer clinical research from more than [--] abstracts across our DXd ADC portfolio including updates from five landmark trials. Click for the link to learn more: #SABCS25 https://bit.ly/48KxdI9 https://bit.ly/48KxdI9" [X Link](https://x.com/anyuser/status/1998003857708687422) 2025-12-08T12:16Z [----] followers, [---] engagements "#BREAKINGNEWS: Our proprietary DXd ADC Technology has been won the Best ADC Platform Technology. In addition our TROP2 directed DXd ADC won the Best ADC Clinical Impact Award and our HER2 directed DXd ADC won the Best ADC Clinical Publication Award by @World_ADC" [X Link](https://x.com/anyuser/status/1989016287184306611) 2025-11-13T17:03Z [----] followers, [---] engagements "#BREAKINGNEWS: @DaiichiSankyoUS has initiated a phase [--] trial evaluating our first STING agonist ADC in patients with advanced metastatic or unresectable solid tumors. #Oncology #CancerResearch https://bit.ly/44129lI https://bit.ly/44129lI" [X Link](https://x.com/anyuser/status/1987855137000259796) 2025-11-10T12:09Z [----] followers, [----] engagements "#BREAKINGNEWS: @DaiichiSankyoUS has initiated the DESTINY-Lung06 phase [--] trial in patients with HER2 Overexpressing Metastatic Non-Squamous Non-Small Cell Lung Cancer. Click for more information: #NonSquamousNSCLC #HER2 https://bit.ly/47txrTm https://bit.ly/47txrTm" [X Link](https://x.com/anyuser/status/1984230620198015158) 2025-10-31T12:06Z [----] followers, [---] engagements "For Alex Borchard building a positive workplace culture and bringing hope to patients with cancer has never been more personal. Read her inspiring story and join us in supporting patients everywhere. https://bit.ly/4oNiHpD https://bit.ly/4oNiHpD" [X Link](https://x.com/anyuser/status/1983263436688478632) 2025-10-28T20:03Z [----] followers, [---] engagements "#BREAKINGNEWS: During @MyESMO Daiichi Sankyo announced data from our TA-MUC1 directed DXd ADC first-in-human phase 1/2 trial. This is the sixth DXd ADC from our oncology pipeline. Click to learn more & follow us during #ESMO25 for the latest data updates from Daiichi Sankyo" [X Link](https://x.com/anyuser/status/1979901319180902826) 2025-10-19T13:23Z [----] followers, [---] engagements "#BREAKINGNEWS: Today at @MyESMO Daiichi Sankyo announced results from the phase [--] part of the REJOICE-Ovarian01 phase 2/3 trial in certain patients with platinum-resistant ovarian cancer. Click the image to learn more. #OvarianCancer #CancerResearch #ESMO25" [X Link](https://x.com/anyuser/status/1979897206326059271) 2025-10-19T13:07Z [----] followers, [---] engagements "#BREAKINGNEWS: Today at @MyESMO Daiichi Sankyo announced late-breaking data from the TROPION-Breast02 phase [--] trial in patients w/ metastatic triple negative breast cancer (#TNBC) in the first-line treatment setting. Click to learn more. #ESMO25" [X Link](https://x.com/anyuser/status/1979867443532288510) 2025-10-19T11:09Z [----] followers, [---] engagements "#BREAKINGNEWS: Today during Presidential Symposium I at @MyESMO Daiichi Sankyo announced new post-neoadjuvant data from the DESTINY-Breast05 phase [--] trial in patients with HER2 positive high-risk early breast cancer. Click the image to learn more. #CancerResearch #HER2" [X Link](https://x.com/anyuser/status/1979561741869863357) 2025-10-18T14:54Z [----] followers, [---] engagements "#BREAKINGNEWS: Today during Presidential Symposium I at @MyESMO Daiichi Sankyo announced the first neoadjuvant data from the DESTINY-Breast11 phase [--] trial for patients with high-risk HER2 positive early-stage breast cancer. Click to learn more. #HER2" [X Link](https://x.com/anyuser/status/1979558640379105786) 2025-10-18T14:42Z [----] followers, [---] engagements Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing
@DaiichiSankyoUS Daiichi Sankyo US
Daiichi Sankyo US posts on X about $8750t, $6417t, $4568t, breast cancer the most. They currently have [-----] followers and [---] posts still getting attention that total [---] engagements in the last [--] hours.
Engagements: [---] #
- [--] Week [---] -68%
- [--] Month [-----] -32%
- [--] Months [------] -91%
- [--] Year [-------] -96%
Mentions: [--] #
- [--] Month [--] -91%
- [--] Months [--] +2.90%
- [--] Year [--] +245%
Followers: [-----] #
- [--] Week [-----] -0.09%
- [--] Month [-----] -0.09%
- [--] Months [-----] +0.39%
- [--] Year [-----] +1.70%
CreatorRank: undefined #
Social Influence
Social category influence stocks technology brands finance countries social networks
Social topic influence $8750t #30, $6417t #30, $4568t #6, breast cancer, click the, award, the first, link, youtube, science
Top accounts mentioned or mentioned by @astrazenecaus @myesmo @merck @sabcssanantonio @iaslc @worldadc @hbanet @galienfdn @derreckkayongo @citeline @usfda @ufpharmacy @hncalliance @afidrocolombia @asco @atoppsummit @gracequest @biopharmadive @pharmavoice @fda
Top assets mentioned Merck & Co., Inc. (MRK)
Top Social Posts
Top posts by engagements in the last [--] hours
"Our heritage is mostly Japanese but there is a dose of New York/New Jersey in our origin story. In [----] Dr. Jokichi Takamine the 1st president of Sankyo Co. Ltd. moved his laboratory from NYC to Clifton NJ where penicillinase was produced during WWII #FlashbackFriday"
X Link 2023-04-28T16:02Z [----] followers, [---] engagements
"Happy #IndependenceDay Whether you celebrate with flags fireworks friends or food take a moment to honor the courage of those who fought for the freedoms we enjoy today. Thank you to all who serve or have served including our @DaiichiSankyoUS veterans https://bit.ly/3NeyKLI https://bit.ly/3NeyKLI"
X Link 2023-07-04T18:01Z [----] followers, [---] engagements
"Our largest fellowship class to date this year we welcomed fellows from as far as Guyana & England to right here in NJ. Watch for more about [--] of our #fellows & their goals post-fellowship - Click for more stories:"
X Link 2023-09-21T14:03Z [----] followers, [---] engagements
"Register now @GalienFdn Week of Innovation series to feature our own Eric Richards Senior Vice President Head of Global Regulatory Affairs Oct. [--]. Register here:"
X Link 2023-10-24T12:05Z [----] followers, [---] engagements
"A powerful reminder of Dr. Martin Luther King Jr.'s enduring legacy of activism service and pursuit of equality we challenge ourselves daily to ask "what are you doing for others" We take action this #MLKDay for each other our communities and the patients we serve"
X Link 2024-01-15T14:30Z [----] followers, [---] engagements
"Founder of the Global Soap Project renowned entrepreneur and advocate for social change @DerreckKayongo inspired us this #Juneteenth to continue persevering for unity diversity and inclusion for alleach other the healthcare industry and the patients we serve"
X Link 2024-06-20T17:12Z [----] followers, [---] engagements
"Whats the scoop on Dale Shuster Senior Vice President Global Head of Precision Medicine at Daiichi Sankyo On #NationalIceCreamDay read about how Dale blends his passions for science ice cream and the ability to care for patients. #DSProud #PrecisionMedicine"
X Link 2024-07-21T12:30Z [----] followers, [---] engagements
"We aim to improve patient lives using groundbreaking technology. Explore our 70+ ongoing clinical trials"
X Link 2024-09-07T12:00Z [----] followers, 2M engagements
"Join us at #ESMO24 Visit booth #303 for an in depth look at Daiichi Sankyos latest R&D developments and learn how our craft is shaping the future of healthcare. And catch up on the latest episodes of Where Craft Meets only on YouTube"
X Link 2024-09-11T12:00Z [----] followers, 281.1K engagements
"Translating science for patients + patient insights for scientists. Gissoo DeCotiis Global Head of Advocacy & Strategic Relations has dedicated her career to ensuring patients are informed heard + supported. Read her story: 👉 #DSProud https://bit.ly/4h9oAdK https://bit.ly/4h9oAdK"
X Link 2024-10-16T15:07Z [----] followers, 167.7K engagements
"#News: During #ESMOAsia24 @DaiichiSankyoUS presented a pooled analysis of the TROPION-Lung05 phase [--] & TROPION-Lung01 phase [--] trials for patients w/ advanced or metastatic EGFR-mutated #NSCLC in collaboration w/ @AstraZenecaUS. Click the image to learn more"
X Link 2024-12-06T14:32Z [----] followers, [---] engagements
"#News: @DaiichiSankyoUS and @Merck have been recognized with the [----] Deal of the Year award by the @Citeline Scrip Awards. A testament to the combined commitment of both companies to help people impacted by cancer around the world"
X Link 2024-12-11T15:00Z [----] followers, [---] engagements
"Honoring Dr. Toshinori Agatsuma Executive Officer Head of Research Daiichi Sankyo Co. Ltd. A true scientific innovator who leaves an immeasurable legacy on the global oncology community as a pioneer of hope for countless people impacted by cancer"
X Link 2024-12-19T15:27Z [----] followers, 406.6K engagements
"🎇Happy Holidays and THANK YOU to all who work tirelessly to help make an impact for those facing life's toughest challenges. Watch our #YearInReview for how our passion for innovation and compassion for patients came to life in [----]. #DSProud"
X Link 2024-12-23T17:15Z [----] followers, [---] engagements
"Explore the journey of Stu Mackey Global Head of Business Development at Daiichi Sankyo as he shares his unique craft of building connections & how it helps bring innovation for the patients of today and tomorrow: https://bit.ly/3PqkxNu https://bit.ly/3PqkxNu"
X Link 2025-01-13T16:14Z [----] followers, 154.8K engagements
"Stu Mackey Global Head of Business Development @DaiichiSankyoUS shares his insights on the art of crafting strategic partnerships that benefit patients partners and investors alike. Watch "Where Craft Meets - Partnerships" to learn more"
X Link 2025-01-13T16:34Z [----] followers, 354.7K engagements
"The art of a "good deal" unfolds in the latest episode of "Where Craft Meets - Partnerships" featuring Stu Mackey @DaiichiSankyoUS Global Head of Business Development. Watch now only on YouTube"
X Link 2025-01-13T16:34Z [----] followers, 310.3K engagements
"At @DaiichiSankyoUS our mission is to deliver innovative medicines to patients in need. Watch Where Craft Meets Partnerships to hear from our Stu Mackey Global Head of Business Development on how he applies his craft of Building Connections with this mission:"
X Link 2025-01-13T16:34Z [----] followers, 326K engagements
"#BreakingNews: Our HER2 directed #ADC has received @US_FDA approval for certain patients with metastatic breast cancer in collaboration w/ @AstraZenecaUS. Click the link to learn more about this latest FDA approval: http://bit.ly/40NYA1f http://bit.ly/40NYA1f"
X Link 2025-01-28T00:24Z [----] followers, [---] engagements
"The potential to improve cancer care and provide new hope to patients is a driving force behind everyone at Daiichi Sankyo. The trust and collaboration from patients allow us to push the limits of what exists today. Together we are creating new standards of care"
X Link 2025-02-13T14:50Z [----] followers, [---] engagements
"#NEWS: Today we announced positive topline overall survival results from the DESTINY-Gastric04 phase [--] trial in patients with previously treated HER2 positive metastatic #GastricCancer in collaboration with @AstraZenecaUS. Click the image to learn more"
X Link 2025-03-03T13:14Z [----] followers, [----] engagements
"@UFPharmacy Thank you we are proud to be a partner in your initiative"
X Link 2025-03-05T20:59Z [----] followers, [--] engagements
"When it comes to medicine development success is achieved by our people passionate experts working to combine their unique crafts with one purpose in mind challenging the status quo to help the patients of tomorrow. Swipe to see what our employees have to say about the team"
X Link 2025-03-13T17:30Z [----] followers, [---] engagements
"In a world overflowing with data and noise the most powerful tool we have is the timeless art of storytelling. Watch Kim Wix Executive Director of Corporate Communications @DaiichiSankyoUS as she shares her unique craft of storytelling to evoke emotion & why choosing the right words has the power to connect and inspire us. Watch here: #Leadership #Innovation #Communication #DSProud https://bit.ly/4kqs9Od https://bit.ly/4kqs9Od"
X Link 2025-03-14T14:02Z [----] followers, [--] engagements
"@hncalliance @hncalliance Thank you we are proud to be a partner in your initiative"
X Link 2025-03-17T18:13Z [----] followers, [--] engagements
"#NEWS: @DaiichiSankyoUS has initiated the DESTINY-Gastric05 phase [--] trial in previously untreated patients with unresectable locally advanced or metastatic HER2 positive gastric or gastroesophageal junction (GEJ) cancer in collaboration with @AstraZenecaUS. Click for more"
X Link 2025-03-31T12:42Z [----] followers, [---] engagements
"#NEWS: Today we announced topline results from the DESTINY-Breast09 phase [--] trial in certain patients with previously untreated HER2 positive metastatic breast cancer in collaboration with @AstraZenecaUS. Click the image to learn more. #mBC #HER2"
X Link 2025-04-21T13:41Z [----] followers, [---] engagements
"@afidro_colombia Thank you we appreciate your message"
X Link 2025-05-07T03:02Z [----] followers, [--] engagements
"#NEWS: Today we announced topline results from the DESTINY-Breast11 phase [--] trial in patients with high-risk #HER2 positive early-stage breast cancer in collaboration with @AstraZenecaUS. Click the image to learn more. #BreastCancer #NationalCancerResearchMonth #OncologyNews"
X Link 2025-05-07T19:21Z [----] followers, [---] engagements
"#BREAKINGNEWS: @DaiichiSankyoUS has initiated the IDeate-Esophageal01 phase [--] trial in certain patients with pretreated advanced or metastatic esophageal squamous cell carcinoma (#ESCC) in collaboration with @Merck. Click the link for more information"
X Link 2025-05-19T13:57Z [----] followers, [---] engagements
"#ASCO25NEWS: Throughout @ASCO we will present more than [--] abstracts across our oncology portfolio including two late-breaking oral presentations. Click to learn more about the specific presentations and follow us during #ASCO25 for more data updates: https://bit.ly/3ZtVSg8 https://bit.ly/3ZtVSg8"
X Link 2025-05-22T22:06Z [----] followers, [---] engagements
"Metastatic Breast Cancer is different. It is more complex than early-stage #BreastCancer requiring alternative treatment plans. Learn about the nuances & how @DaiichiSankyoUS is developing innovations that may change the treatment landscape for patients. Click now to read. #mBC"
X Link 2025-05-29T13:41Z [----] followers, [---] engagements
"#BREAKINGNEWS: Today at a late breaking oral presentation at #ASCO25 positive results from the DESTINY-Gastric04 phase [--] trial were presented in collaboration with @AstraZenecaUS. Click the image to learn more. #GastricCancer #HER2Positive"
X Link 2025-05-31T12:14Z [----] followers, [---] engagements
"#NEWS: Results from the TROPION-Lung02 & TROPION-Lung04 phase 1b trials & NeoCOAST-2 phase [--] trial showing promising tumor responses in patients with early and advanced #NSCLC were presented today at #ASCO25 in collaboration with @AstraZenecaUS. Click the image to learn more"
X Link 2025-06-01T13:16Z [----] followers, [---] engagements
"#BREAKINGNEWS: Today during a special late breaking oral presentation at #ASCO25 results from the DESTINY-Breast09 phase [--] trial were presented in collaboration with @AstraZenecaUS. Click the image to learn more. #mBC #HER2Positive"
X Link 2025-06-02T12:09Z [----] followers, [---] engagements
"@atoppsummit @atoppsummit Thank you we are proud to be a sponsor for this event"
X Link 2025-06-02T20:15Z [----] followers, [--] engagements
"@Grace_Quest Thank you we appreciate your message"
X Link 2025-06-03T03:34Z [----] followers, [--] engagements
"Register now for the @BioPharmaDive & @pharmavoice virtual event this Thursday featuring @DaiichiSankyoUS CEO Ken Keller as he discusses the ins and outs of Building a blockbuster ADC franchise. Register here: https://bit.ly/43EKRdd https://bit.ly/43EKRdd"
X Link 2025-06-03T14:48Z [----] followers, [---] engagements
"#BREAKINGNEWS: @DaiichiSankyoUS has initiated the DESTINY-Endometrial01 phase [--] trial in patients with previously untreated HER2 expressing advanced endometrial cancer in collaboration with @AstraZenecaUS. Click the image for more information. #EndometrialCancer"
X Link 2025-06-09T13:02Z [----] followers, [---] engagements
"#BREAKINGNEWS: @DaiichiSankyoUS has initiated the IDeate-Prostate01 phase [--] trial in certain patients with pretreated metastatic castration-resistant prostate cancer in collaboration with @Merck. Click the link for more information: https://bit.ly/3G7ERSx https://bit.ly/3G7ERSx"
X Link 2025-06-18T11:13Z [----] followers, [---] engagements
"#BreakingNews: Today the @FDA approved our TROP2 directed DXd #ADC for previously treated adult patients with locally advanced or metastatic #EGFR-mutated #NSCLC in collaboration w/ @AstraZenecaUS. Click the image to learn more"
X Link 2025-06-23T21:33Z [----] followers, [---] engagements
"There is more to metastatic breast cancer than the science. Patricia Judson M.D. Vice President U.S. Medical Affairs discusses the importance of recognizing the different tone and unique needs of patients with #mBC. Click now to read the full story. #MetastaticBreastCancer"
X Link 2025-06-26T16:49Z [----] followers, [---] engagements
"Behind every medicine is a story. At Daiichi Sankyo our experts combine precision and purpose to drive innovation. Discover how their unique crafts help transform science into medicines for the patients of today and tomorrow. 🔗 https://bit.ly/3TOL88S https://bit.ly/3TOL88S"
X Link 2025-07-08T14:30Z [----] followers, [---] engagements
"#BREAKINGNEWS: Today we announced the publication of final long-term efficacy and safety results from the open-label extension of the ENLIVEN phase [--] trial of our medicine in patients with tenosynovial giant cell tumor. Click the image to learn more. #TGCT"
X Link 2025-07-09T12:10Z [----] followers, [---] engagements
"#NEWS: The FDA granted Breakthrough Therapy Designation for our HER2 directed #ADC as part of a combination regimen for the first-line treatment of adult patients w/ HER2 positive #mBC in collaboration w/ @AstraZenecaUS. This is the 13th BTD across our oncology portfolio"
X Link 2025-07-17T12:06Z [----] followers, [---] engagements
"Ray Bedeaux simplifies complex oncology processes helping Daiichi Sankyo focus on what matters mostpatients. Join us and help shape the future of healthcare together"
X Link 2025-07-21T14:28Z [----] followers, 203.6K engagements
"Delivering medicines is complex but Ray Bedeauxs craft of synthesis ensures Daiichi Sankyo focuses on what matters most for patients. Discover how Daiichi Sankyo is shaping the future of medicine"
X Link 2025-07-21T14:28Z [----] followers, 226.9K engagements
"Ray Bedeaux turns complexity into impact. His craft "Synthesis" ensures the critical medicines we create reach patients who need them most. Share your unique craft below and how it is shaping the future. Read our Company Brochure to learn how we are making an impact: https://bit.ly/3IEHQmr https://bit.ly/3IEHQmr"
X Link 2025-07-21T14:59Z [----] followers, [---] engagements
"This is the story of a promise kept. After witnessing his father experience a devastating battle with cancer Ray Bedeaux made a promiseto dedicate himself to the field of oncology. Dont miss this inspiring story: #WhereCraftMeets #Oncology #PatientCare #Innovation https://bit.ly/4ooqAST https://bit.ly/4ooqAST https://bit.ly/4ooqAST https://bit.ly/4ooqAST"
X Link 2025-08-06T16:19Z [----] followers, [---] engagements
"#BREAKINGNEWS: At the [----] @IASLC Annual Meeting we will share data during a late-breaking oral presentation from the IDeate-Lung01 phase [--] trial for patients with pretreated extensive-stage small cell lung cancer. Click to learn more & follow us during #WCLC25 for more"
X Link 2025-08-14T12:15Z [----] followers, [---] engagements
"#BREAKINGNEWS: The FDA granted Breakthrough Therapy Designation for one of our investigational medicines for adult patients with extensive-stage small cell lung cancer in collaboration with @Merck. This is the 14th BTD across our oncology portfolio. #SCLC #CancerResearch"
X Link 2025-08-18T11:20Z [----] followers, [---] engagements
"The not-so-hidden secret to our hiring success Empathy transparency and culture. Read how Daiichi Sankyo builds teams that thrive"
X Link 2025-08-28T19:58Z [----] followers, [---] engagements
"#BREAKINGNEWS: @DaiichiSankyoUS has initiated the HERTHENA-Breast04 phase [--] trial in patients with unresectable locally advanced or metastatic hormone receptor (HR) positive HER2 negative breast cancer in collaboration with @Merck. Click the link for more information. #mBC"
X Link 2025-08-29T12:08Z [----] followers, [---] engagements
"#BREAKINGNEWS: Late-breaking data from the IDeate-Lung01 phase [--] trial in patients with pretreated extensive-stage small cell lung cancer were presented during a late-breaking oral presentation at the [----] @IASLC Annual Meeting in collaboration with @Merck. Learn more. #WCLC25"
X Link 2025-09-07T15:23Z [----] followers, [---] engagements
"#BREAKINGNEWS: The FDA granted Breakthrough Therapy Designation for our investigational medicine for certain adult patients with platinum-resistant ovarian cancer being developed in collaboration w/ @Merck. Click the image to learn more. #OvarianCancer #CancerResearch"
X Link 2025-09-15T11:14Z [----] followers, [---] engagements
"#BREAKINGNEWS: The FDA accepted & granted Priority Review of the sBLA for our HER2 directed DXd ADC as part of a combination regimen for the first-line treatment of adult patients w/ metastatic HER2 positive breast cancer in collaboration w/ @AstraZenecaUS. #BreastCancer"
X Link 2025-09-24T10:58Z [----] followers, [---] engagements
"#NEWS: Today we announced positive topline results from the DESTINY-Breast05 phase [--] trial for patients with high-risk HER2 positive early breast cancer in collaboration w/ @AstraZenecaUS; our second positive phase [--] trial in HER2 positive early breast cancer. Click for more"
X Link 2025-09-29T12:11Z [----] followers, [---] engagements
"After a 2-year PharmD fellowship Andrew found his calling as a medical reviewer. Learn how he honors his mother and empowers patients every day by translating complex science into trust"
X Link 2025-09-30T14:34Z [----] followers, [---] engagements
"Our team at Daiichi Sankyo is committed to raising awareness this month for #breastcancer research. Watch a message from our CEO Ken Keller to learn what #BCAM means to us"
X Link 2020-10-15T12:53Z [----] followers, [--] engagements
"It was incredible how these doctors & nurses were able to repair this broken heart no bigger than a walnut. Michael Grosso VP Global Head of Specialty Medicine Development at Daiichi Sankyo discusses life as a former heart surgeon & his fulfilling career. #Heartmonth"
X Link 2024-02-20T19:03Z [----] followers, [---] engagements
"#BreakingNews: Throughout @SABCSSanAntonio @myESMO and @ASH_hematology @Daiichi Sankyo US will highlight progress across our oncology portfolio in multiple solid and blood cancers. Click the image for full details on our #SABCS24 #ESMOASIA24 & #ASH24 data"
X Link 2024-12-02T13:05Z [----] followers, [---] engagements
"Daiichi Sankyo today announced Hiroyuki Okuzawa as the new global CEO effective April [--] [----]. Mr. Okuzawa currently Representative Director President and COO will succeed Sunao Manabe who will continue as the Representative Director and Executive Chairperson"
X Link 2025-01-31T12:59Z [----] followers, [---] engagements
"On #WorldCancerDay we stand united with the global oncology community to recognize and honor the unique stories of those impacted by cancer. No two cancer treatment journeys are alike but we all share the same goal. #UnitedByUnique"
X Link 2025-02-04T12:17Z [----] followers, [---] engagements
"Patients don't think like scientists - and they shouldn't have to. @GDbinkys team helps translate highly complex topics like #CancerResearch into easy-to-understand resources for patients and caregivers. #PatientCare #Advocacy https://bit.ly/4aiXFsL https://bit.ly/4aiXFsL"
X Link 2025-02-11T17:30Z [----] followers, [---] engagements
"Simon King a seasoned HR leader with a scientific foundation honed his craft of "listening" to uncover insights and perspectives from others that make a difference. Join us for a conversation with our @DaiichiSankyoUS Chief People Officer to learn about his career journey and his unique perspective on teamwork. Watch the full episode now on YouTube: https://bit.ly/3Qqyqvl https://bit.ly/3Qqyqvl"
X Link 2025-02-24T15:29Z [----] followers, [--] engagements
"#BREAKINGNEWS: The FDA accepted the sBLA for our HER2 directed DXd #ADC followed by a combination regimen for the treatment of adult patients w/ high-risk #HER2 positive early-stage breast cancer prior to surgery in collaboration w/ @AstraZenecaUS. Click to learn more"
X Link 2025-10-01T11:17Z [----] followers, [---] engagements
"#BREAKINGNEWS: Today we announced the establishment of the Daiichi Sankyo Research Institute in San Diego marking our third research institute outside of our flagship research center in Japan. Click the image to learn more. #ResearchInstitute #PharmaResearch"
X Link 2025-10-02T13:09Z [----] followers, [---] engagements
"#BREAKINGNEWS: Today we announced positive topline results from the TROPION-Breast02 phase [--] trial for patients with locally recurrent inoperable or metastatic triple negative breast cancer (#TNBC) in collaboration with @AstraZenecaUS. Click the image to learn more. #TNBC"
X Link 2025-10-06T11:18Z [----] followers, [---] engagements
"#BREAKINGNEWS: Daiichi Sankyo joins @BioLabs the leading international innovation platform and network of premier shared laboratory spaces as Platinum Sponsor; providing BioLabs with direct access to Daiichi Sankyo scientific leaders and expertise. Click the image for more"
X Link 2025-10-07T11:15Z [----] followers, [---] engagements
"#NEWS: Throughout @MyESMO we will present more than [--] abstracts including two back-to-back presentations during Presidential Symposium I featuring data from the DESTINY-Breast11 & DESTINY-Breast05 phase [--] trials & late-breaking data from the TROPION-Breast02 phase [--] trial"
X Link 2025-10-13T11:28Z [----] followers, [---] engagements
"#BREAKINGNEWS: Today during a mini oral session at @MyESMO Daiichi Sankyo announced initial results from one substudy of the TROPION-PanTumor03 phase [--] trial in patients with locally advanced or metastatic urothelial cancer. Click to learn more. #BladderCancer #ESMO25"
X Link 2025-10-17T14:15Z [----] followers, [---] engagements
"#BREAKINGNEWS: Today during Presidential Symposium I at @MyESMO Daiichi Sankyo announced the first neoadjuvant data from the DESTINY-Breast11 phase [--] trial for patients with high-risk HER2 positive early-stage breast cancer. Click to learn more. #HER2"
X Link 2025-10-18T14:42Z [----] followers, [---] engagements
"#BREAKINGNEWS: Today during Presidential Symposium I at @MyESMO Daiichi Sankyo announced new post-neoadjuvant data from the DESTINY-Breast05 phase [--] trial in patients with HER2 positive high-risk early breast cancer. Click the image to learn more. #CancerResearch #HER2"
X Link 2025-10-18T14:54Z [----] followers, [---] engagements
"#BREAKINGNEWS: Today at @MyESMO Daiichi Sankyo announced late-breaking data from the TROPION-Breast02 phase [--] trial in patients w/ metastatic triple negative breast cancer (#TNBC) in the first-line treatment setting. Click to learn more. #ESMO25"
X Link 2025-10-19T11:09Z [----] followers, [---] engagements
"#BREAKINGNEWS: Today at @MyESMO Daiichi Sankyo announced results from the phase [--] part of the REJOICE-Ovarian01 phase 2/3 trial in certain patients with platinum-resistant ovarian cancer. Click the image to learn more. #OvarianCancer #CancerResearch #ESMO25"
X Link 2025-10-19T13:07Z [----] followers, [---] engagements
"#BREAKINGNEWS: During @MyESMO Daiichi Sankyo announced data from our TA-MUC1 directed DXd ADC first-in-human phase 1/2 trial. This is the sixth DXd ADC from our oncology pipeline. Click to learn more & follow us during #ESMO25 for the latest data updates from Daiichi Sankyo"
X Link 2025-10-19T13:23Z [----] followers, [---] engagements
"For Alex Borchard building a positive workplace culture and bringing hope to patients with cancer has never been more personal. Read her inspiring story and join us in supporting patients everywhere. https://bit.ly/4oNiHpD https://bit.ly/4oNiHpD"
X Link 2025-10-28T20:03Z [----] followers, [---] engagements
"#BREAKINGNEWS: @DaiichiSankyoUS has initiated the DESTINY-Lung06 phase [--] trial in patients with HER2 Overexpressing Metastatic Non-Squamous Non-Small Cell Lung Cancer. Click for more information: #NonSquamousNSCLC #HER2 https://bit.ly/47txrTm https://bit.ly/47txrTm"
X Link 2025-10-31T12:06Z [----] followers, [---] engagements
"#BREAKINGNEWS: @DaiichiSankyoUS has initiated a phase [--] trial evaluating our first STING agonist ADC in patients with advanced metastatic or unresectable solid tumors. #Oncology #CancerResearch https://bit.ly/44129lI https://bit.ly/44129lI"
X Link 2025-11-10T12:09Z [----] followers, [----] engagements
"#BREAKINGNEWS: Our proprietary DXd ADC Technology has been won the Best ADC Platform Technology. In addition our TROP2 directed DXd ADC won the Best ADC Clinical Impact Award and our HER2 directed DXd ADC won the Best ADC Clinical Publication Award by @World_ADC"
X Link 2025-11-13T17:03Z [----] followers, [---] engagements
"#BREAKINGNEWS: During @SABCSSanAntonio we will present new breast cancer clinical research from more than [--] abstracts across our DXd ADC portfolio including updates from five landmark trials. Click for the link to learn more: #SABCS25 https://bit.ly/48KxdI9 https://bit.ly/48KxdI9"
X Link 2025-12-08T12:16Z [----] followers, [---] engagements
"#BREAKINGNEWS: We initiated the DESTINY-Ovarian01 phase [--] trial evaluating our HER2 directed ADC as a combination first-line maintenance therapy in patients with HER2 expressing advanced high-grade epithelial ovarian cancer. https://bit.ly/44iOdE5 https://bit.ly/44iOdE5"
X Link 2025-12-09T12:34Z [----] followers, [---] engagements
"#BREAKINGNEWS: The FDA has approved our HER2 directed DXd ADC as part of a combination regimen for the first-line treatment of adult patients with HER2 positive metastatic breast cancer in collaboration with @AstraZenecaUS. #BreastCancerResearch https://bit.ly/3XWtnXq https://bit.ly/3XWtnXq"
X Link 2025-12-15T20:01Z [----] followers, [---] engagements
"#ICYM any of the @DaiichiSankyoUS R&D milestones throughout [----] our annual Science & Technology Day is now available on demand. Hear from key leaders as they share significant clinical achievements across our #oncology portfolio. Click here: https://bit.ly/4p0D7uK https://bit.ly/4p0D7uK"
X Link 2025-12-17T14:00Z [----] followers, [---] engagements
"#BREAKINGNEWS: @DaiichiSankyoUS has initiated the DESTINY-Endometrial02 phase [--] trial evaluating our HER2 directed ADC as an adjuvant treatment in patients with HER2 expressing #endometrialcancer in collaboration with @AstraZenecaUS. Click for more info: https://bit.ly/3KVbMwf https://bit.ly/3KVbMwf"
X Link 2025-12-22T12:00Z [----] followers, [---] engagements
"#BREAKINGNEWS: The FDA has granted Breakthrough Therapy Designation for our HER2-directed DXd ADC as a post-neoadjuvant treatment in patients with HER2 positive early breast cancer in collaboration w/ @AstraZenecaUS. Click the link to learn more: https://bit.ly/3KYdYTK https://bit.ly/3KYdYTK"
X Link 2025-12-22T13:37Z [----] followers, [---] engagements
"From all of us at Daiichi Sankyowishing you a healthy peaceful and hopeful New Year. Heres to creating better tomorrows together"
X Link 2026-01-01T12:03Z [----] followers, [---] engagements
"#BREAKINGNEWS: @DaiichiSankyoUS has initiated the TROPION-Lung17 phase [--] trial in certain patients with previously treated TROP2 NMR positive locally advanced or metastatic nonsquamous nonsmall cell lung cancer in collaboration with @AstraZenecaUS. Learn more: https://bit.ly/3YCkaUA https://bit.ly/3YCkaUA"
X Link 2026-01-13T12:06Z [----] followers, [---] engagements
"#BREAKINGNEWS: The FDA has granted Priority Review for the sBLA for our TROP2 directed DXd ADC for the treatment of certain adult patients with unresectable or metastatic triple negative breast cancer in collaboration with @AstraZenecaUS. #BreastCancerResearch #TNBC https://bit.ly/3M9rxAe https://bit.ly/3M9rxAe"
X Link 2026-02-03T12:02Z [----] followers, [---] engagements
"#BREAKINGNEWS: @DaiichiSankyoUS has initiated a phase 1/2 trial evaluating our CD37 directed DXd ADC in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Learn more: https://bit.ly/4qcdVSD https://bit.ly/4qcdVSD"
X Link 2026-02-04T12:04Z [----] followers, [---] engagements
"From leadership development to transformative cancer medicines our enterprise approach earned the first Global Impact Award Honorable Mention from @HBAnet. Thank you to our global teams. #DSProud #AscendWithHBA Today we are thrilled to announce @DaiichiSankyoUS as the winner of the [----] HBA Global Impact Award Honorable Mention Distinction Read the full announcement here: https://t.co/Qh8IsYISCh https://t.co/pxs492VZHY Today we are thrilled to announce @DaiichiSankyoUS as the winner of the [----] HBA Global Impact Award Honorable Mention Distinction Read the full announcement here:"
X Link 2026-02-10T14:24Z [----] followers, [---] engagements
"Every role at Daiichi Sankyo is part of a bigger story. See how Tamys craftorchestrationconnects innovation to impact turning science into meaningful progress for patients"
X Link 2026-02-11T20:11Z [----] followers, 11.1K engagements
"Behind every medicine is a story. Meet Ray Bedeaux whose craft of synthesis helps Daiichi Sankyo simplify complex processes to focus on what matters mostpatients. Follow for the stories behind our medicines"
X Link 2026-02-11T20:11Z [----] followers, 12.7K engagements
"Behind every medicine is a story. Meet Ray Bedeaux whose craft of synthesis helps Daiichi Sankyo simplify complex processes to focus on what matters mostpatients. Follow for the stories behind our medicines"
X Link 2026-02-11T20:11Z [----] followers, 41.6K engagements
"From leadership development to transformative cancer medicines our enterprise approach earned the first Global Impact Award Honorable Mention from @HBAnet. Thank you to our global teams. #DSProud #AscendWithHBA Today we are thrilled to announce @DaiichiSankyoUS as the winner of the [----] HBA Global Impact Award Honorable Mention Distinction Read the full announcement here: https://t.co/Qh8IsYISCh https://t.co/pxs492VZHY Today we are thrilled to announce @DaiichiSankyoUS as the winner of the [----] HBA Global Impact Award Honorable Mention Distinction Read the full announcement here:"
X Link 2026-02-10T14:24Z [----] followers, [---] engagements
"Today we are thrilled to announce @DaiichiSankyoUS as the winner of the [----] HBA Global Impact Award Honorable Mention Distinction Read the full announcement here: https://hbanet.org/news/2026/02/5/daiichi-sankyo-honored-global-impact-award-honorable-mention-healthcare https://hbanet.org/news/2026/02/5/daiichi-sankyo-honored-global-impact-award-honorable-mention-healthcare"
X Link 2026-02-10T14:00Z [----] followers, [---] engagements
"#BREAKINGNEWS: @DaiichiSankyoUS has initiated a phase 1/2 trial evaluating our CD37 directed DXd ADC in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Learn more: https://bit.ly/4qcdVSD https://bit.ly/4qcdVSD"
X Link 2026-02-04T12:04Z [----] followers, [---] engagements
"#BREAKINGNEWS: The FDA has granted Priority Review for the sBLA for our TROP2 directed DXd ADC for the treatment of certain adult patients with unresectable or metastatic triple negative breast cancer in collaboration with @AstraZenecaUS. #BreastCancerResearch #TNBC https://bit.ly/3M9rxAe https://bit.ly/3M9rxAe"
X Link 2026-02-03T12:02Z [----] followers, [---] engagements
"#BREAKINGNEWS: @DaiichiSankyoUS has initiated the TROPION-Lung17 phase [--] trial in certain patients with previously treated TROP2 NMR positive locally advanced or metastatic nonsquamous nonsmall cell lung cancer in collaboration with @AstraZenecaUS. Learn more: https://bit.ly/3YCkaUA https://bit.ly/3YCkaUA"
X Link 2026-01-13T12:06Z [----] followers, [---] engagements
"From all of us at Daiichi Sankyowishing you a healthy peaceful and hopeful New Year. Heres to creating better tomorrows together"
X Link 2026-01-01T12:03Z [----] followers, [---] engagements
"#BREAKINGNEWS: The FDA has granted Breakthrough Therapy Designation for our HER2-directed DXd ADC as a post-neoadjuvant treatment in patients with HER2 positive early breast cancer in collaboration w/ @AstraZenecaUS. Click the link to learn more: https://bit.ly/3KYdYTK https://bit.ly/3KYdYTK"
X Link 2025-12-22T13:37Z [----] followers, [---] engagements
"#BREAKINGNEWS: @DaiichiSankyoUS has initiated the DESTINY-Endometrial02 phase [--] trial evaluating our HER2 directed ADC as an adjuvant treatment in patients with HER2 expressing #endometrialcancer in collaboration with @AstraZenecaUS. Click for more info: https://bit.ly/3KVbMwf https://bit.ly/3KVbMwf"
X Link 2025-12-22T12:00Z [----] followers, [---] engagements
"#ICYM any of the @DaiichiSankyoUS R&D milestones throughout [----] our annual Science & Technology Day is now available on demand. Hear from key leaders as they share significant clinical achievements across our #oncology portfolio. Click here: https://bit.ly/4p0D7uK https://bit.ly/4p0D7uK"
X Link 2025-12-17T14:00Z [----] followers, [---] engagements
"#BREAKINGNEWS: The FDA has approved our HER2 directed DXd ADC as part of a combination regimen for the first-line treatment of adult patients with HER2 positive metastatic breast cancer in collaboration with @AstraZenecaUS. #BreastCancerResearch https://bit.ly/3XWtnXq https://bit.ly/3XWtnXq"
X Link 2025-12-15T20:01Z [----] followers, [---] engagements
"#BREAKINGNEWS: We initiated the DESTINY-Ovarian01 phase [--] trial evaluating our HER2 directed ADC as a combination first-line maintenance therapy in patients with HER2 expressing advanced high-grade epithelial ovarian cancer. https://bit.ly/44iOdE5 https://bit.ly/44iOdE5"
X Link 2025-12-09T12:34Z [----] followers, [---] engagements
"#BREAKINGNEWS: During @SABCSSanAntonio we will present new breast cancer clinical research from more than [--] abstracts across our DXd ADC portfolio including updates from five landmark trials. Click for the link to learn more: #SABCS25 https://bit.ly/48KxdI9 https://bit.ly/48KxdI9"
X Link 2025-12-08T12:16Z [----] followers, [---] engagements
"#BREAKINGNEWS: Our proprietary DXd ADC Technology has been won the Best ADC Platform Technology. In addition our TROP2 directed DXd ADC won the Best ADC Clinical Impact Award and our HER2 directed DXd ADC won the Best ADC Clinical Publication Award by @World_ADC"
X Link 2025-11-13T17:03Z [----] followers, [---] engagements
"#BREAKINGNEWS: @DaiichiSankyoUS has initiated a phase [--] trial evaluating our first STING agonist ADC in patients with advanced metastatic or unresectable solid tumors. #Oncology #CancerResearch https://bit.ly/44129lI https://bit.ly/44129lI"
X Link 2025-11-10T12:09Z [----] followers, [----] engagements
"#BREAKINGNEWS: @DaiichiSankyoUS has initiated the DESTINY-Lung06 phase [--] trial in patients with HER2 Overexpressing Metastatic Non-Squamous Non-Small Cell Lung Cancer. Click for more information: #NonSquamousNSCLC #HER2 https://bit.ly/47txrTm https://bit.ly/47txrTm"
X Link 2025-10-31T12:06Z [----] followers, [---] engagements
"For Alex Borchard building a positive workplace culture and bringing hope to patients with cancer has never been more personal. Read her inspiring story and join us in supporting patients everywhere. https://bit.ly/4oNiHpD https://bit.ly/4oNiHpD"
X Link 2025-10-28T20:03Z [----] followers, [---] engagements
"#BREAKINGNEWS: During @MyESMO Daiichi Sankyo announced data from our TA-MUC1 directed DXd ADC first-in-human phase 1/2 trial. This is the sixth DXd ADC from our oncology pipeline. Click to learn more & follow us during #ESMO25 for the latest data updates from Daiichi Sankyo"
X Link 2025-10-19T13:23Z [----] followers, [---] engagements
"#BREAKINGNEWS: Today at @MyESMO Daiichi Sankyo announced results from the phase [--] part of the REJOICE-Ovarian01 phase 2/3 trial in certain patients with platinum-resistant ovarian cancer. Click the image to learn more. #OvarianCancer #CancerResearch #ESMO25"
X Link 2025-10-19T13:07Z [----] followers, [---] engagements
"#BREAKINGNEWS: Today at @MyESMO Daiichi Sankyo announced late-breaking data from the TROPION-Breast02 phase [--] trial in patients w/ metastatic triple negative breast cancer (#TNBC) in the first-line treatment setting. Click to learn more. #ESMO25"
X Link 2025-10-19T11:09Z [----] followers, [---] engagements
"#BREAKINGNEWS: Today during Presidential Symposium I at @MyESMO Daiichi Sankyo announced new post-neoadjuvant data from the DESTINY-Breast05 phase [--] trial in patients with HER2 positive high-risk early breast cancer. Click the image to learn more. #CancerResearch #HER2"
X Link 2025-10-18T14:54Z [----] followers, [---] engagements
"#BREAKINGNEWS: Today during Presidential Symposium I at @MyESMO Daiichi Sankyo announced the first neoadjuvant data from the DESTINY-Breast11 phase [--] trial for patients with high-risk HER2 positive early-stage breast cancer. Click to learn more. #HER2"
X Link 2025-10-18T14:42Z [----] followers, [---] engagements
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing